In short
- Incretins = gut hormones that boost insulin release after a meal.
- The two known incretins are GLP-1 and GIP.
- In type 2 diabetes the incretin effect is clearly weakened – one starting point for GLP-1 medications.
Meaning
Incretins are hormones from the gut that promote insulin release. Hormone-producing cells in the intestinal lining make them as soon as nutrients arrive. The two known incretins are GIP (glucose-dependent insulinotropic polypeptide), made mainly in the upper small intestine, and GLP-1 (glucagon-like peptide 1), made further down the gut. Both are quickly broken down by the enzyme DPP-4.
The incretin effect
When you drink a glucose solution, the pancreas releases far more insulin than when the same blood glucose curve is produced by an infusion straight into a vein. That gap is called the incretin effect – it exists because incretins are only released when glucose passes through the gut. In a classic study of 8 metabolically healthy people and 14 people with type 2 diabetes, it accounted for about 73% of the insulin response in the healthy group but only about 36% in type 2 diabetes.
Link to the medications
In type 2 diabetes the pancreas still responds to GLP-1 but hardly to GIP. GLP-1 receptor agonists such as semaglutide build on that: modified GLP-1 molecules that act for days. Tirzepatide also activates the GIP receptor – see semaglutide vs tirzepatide. How GLP-1 works on the stomach and brain is explained in lesson 1 of the GLP-1 basics course.
Everyday example
The incretin effect is one reason an oral glucose tolerance test measures something different from a single fasting value: it reflects how the gut and pancreas work together when you eat. In the BeBetr app you can follow glucose and HbA1c from your lab reports over time and log them alongside your medication and meals.
Sources
- Nauck M et al.: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986
- Nauck MA, Meier JJ: The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016
- Drucker DJ: Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018
Written by the BeBetr editorial team with AI assistance; facts checked against the sources listed (as of Nov 21, 2026). This content is for information only and does not replace medical advice, diagnosis or treatment.
BeBetr